INTRODUCTION
The lymphatic vasculature consists of a network of lymph vessels that drain interstitial fluid from tissues and return it to the blood. It is also essential for immune surveillance. However, increased lymphangiogenesis also contributes to tumor metastasis and various inflammatory diseases, while insufficient lymph vessel growth or dysfunction causes lymphedema (Albrecht and Christofori, 2011; Alitalo, 2011; Bonnal et al., 2003; Christiansen and Detmar, 2011; Martinez-Corral and Makinen, 2013) . Blocking lymphangiogenesis may offer therapeutic benefit to limit tumor spread.
Hypoxia promotes the growth of blood vessels (angiogenesis), but only limited data are available on whether and how hypoxia regulates lymphangiogenesis. Nevertheless, lymph vessels are often located in remote areas away from oxygencarrying blood vessels and do not contain oxygen-carrying red blood cells; they are thus exposed to a milieu with very low oxygen levels (Guzy et al., 2008; Ivanovic, 2009) . Some correlative studies suggest a link among tumor hypoxia, the hypoxia-inducible transcription factor HIF-1a, and lymphangiogenesis (Schoppmann et al., 2006; Tao et al., 2006) . Another study reported that HIF-1a promotes lymphatic metastasis by transcriptional activation of the lymphangiogenic factor platelet derived growth factor B (Schito et al., 2012) . HIF-1a also stimulates transcription of Prox-1, another lymph-angiogenic factor (Zhou et al., 2013) . However, whether hypoxia signaling (and in particular HIF-1a) regulates the expression of vascular endothelial growth factor C (VEGF-C), one of the key lymphangiogenic factors (Alitalo and Detmar, 2012) , remains unknown. Only a single report documented an associative correlation between HIF-1a and VEGF-C in cancer (Liang et al., 2008) . It is also unknown whether VEGF-C expression in hypoxic conditions relies on transcriptional or translational mechanisms.
When cells are exposed to low oxygen levels, they suppress general protein synthesis in order to save energy (Kaelin and Ratcliffe, 2008; Majmundar et al., 2010; Maxwell, 2005; Semenza, 2012) . Hypoxia inhibits mRNA translation by affecting the activity of two kinases, mTOR and PERK (Larsson et al., 2013; Silvera and Schneider, 2009 ). Inactivation of mTOR results in hypophosphorylation of eIF4E-binding proteins (4E-BP), which promotes the sequestering of eIF4E, a factor necessary for cap-dependent translation (Martineau et al., 2013; Richter and Sonenberg, 2005) . Hypoxic activation of PERK is mediated by the unfolded protein response and inhibits translation by phosphorylating the translation initiation factor eIF2-a (Koumenis and Wouters, 2006) .
Other mRNAs are translated in hypoxic conditions by an alternative mechanism, mediated by internal ribosome entry sites (IRESs) located in their 5 0 UTRs, which allows the ribosome to be recruited to a site that is at a considerable distance from the cap structure, most frequently in the presence of trans-acting factors (Spriggs et al., 2008; Vagner et al., 2001 ). Many cellular mRNAs have now been documented to contain IRESs. The majority of identified IRESs are found in mRNAs of proteins that are associated with the control of cell growth and death, including growth factors, proto-oncogenes and proteins required for apoptosis (Bushell et al., 2004) . IRES elements have also been identified in VEGF-A and fibroblast growth factor 2 mRNA sequences and are activated by hypoxia to stimulate angiogenesis (Bornes et al., 2007) . However, since it is unknown if IRES-dependent expression of VEGF-C in hypoxic conditions regulates lymphangiogenesis, we characterized IRES-dependent induction of VEGF-C in hypoxic tumors and lymph nodes. 
RESULTS

Coexpression of VEGF-C and 4E-BP1 in Tumor Cells
We examined by immunohistochemistry (IHC) the expression levels of VEGF-C in human healthy breast specimens, tumor biopsies of invasive ductal carcinomas, and draining metastatic lymph nodes. Fifteen tumor biopsy specimens and their sentinel nodes were analyzed. Immunoreactive VEGF-C levels were moderate in healthy tissues but elevated in tumor samples ( Figures 1A-1C ). VEGF-C was undetectable in healthy lymph nodes but upregulated in metastatic tumor cells in lymph nodes ( Figures 1D-1F ). Notably, 4E-BP1, a negative regulator of cap-dependent mRNA translation, was overexpressed in tumors and metastatic lymph nodes as compared to healthy epithelium and noninvaded lymph nodes ( Figures 1G-1J ). Since overexpression of 4E-BP1 inhibits cap-dependent translation induced by hypoxia in tumors (Braunstein et al., 2007) , these findings raised the question whether VEGF-C translation in tumors and metastatic lymph nodes relied on a cap-independent regulation of VEGF-C translation.
VEGF-C mRNA Is Reduced while VEGF-C Protein Is Increased in Tumors
We used three different mouse tumor models known to induce lymphangiogenesis and to metastasize via lymph vessels: Capan-1, a xenograft of human pancreatic adenocarcinoma; 4T1, an orthotopic syngeneic mouse model of metastatic breast cancer; and a syngeneic subcutaneous model of Lewis lung carcinoma (LLC) (Deer et al., 2010; Garmy-Susini et al., 2010; Pulaski and Ostrand-Rosenberg, 2001 ). When studying the expression of VEGF-C in primary tumor extracts during tumor progression, we found that VEGF-C mRNA levels were decreased (Figures 2A-2C ), while human VEGF-C protein levels were increased in the three tumor cell types, as observed by a human VEGF-C-specific ELISA ( Figure 2D ) and by immunoblotting ( Figures 2E and 2F ). These data suggested that induction of VEGF-C expression occurred via a posttranscriptional mechanism. Use of murine VEGF-C-specific primers in the human Capan-1 tumor model revealed that stromal cells did not compensate for the reduced human VEGF-C mRNA levels by upregulating murine VEGF-C transcript levels ( Figure S1 ). Staining for the lymphatic endothelial cell marker LYVE-1 complemented with quantification of lymph vessel area showed that lymphangiogenesis increased during tumor progression ( Figures 2G-2O ), in agreement with the enhanced VEGF-C protein levels.
We studied the phosphorylation status of 4E-BP1 by immunoblotting. 4E-BP1 can be hypophosphorylated (designated a-form) or hyperphosphorylated (designated b and g forms). In its hypophosphorylated state, 4E-BP1 inhibits cap-dependent translation initiation by sequestering eIF-4E (Martineau et al., 2013; Richter and Sonenberg, 2005) . During tumor progression, total 4E-BP1 protein levels increased and 4E-BP1 became increasingly hypophosphorylated, as evidenced by the shift to a lower molecular weight (Figures 2E and 2F) . We also analyzed eIF2a phosphorylation using antibodies recognizing phosphorylated and total eIF2a, as eIF2a phosphorylation downregulates protein synthesis in various stress conditions, including hypoxia (Koumenis and Wouters, 2006) . Notably, phosphorylated eIF2a (p-eIF2a) levels increased during tumor progression ( Figures 2E and 2F) . Thus, decreased VEGF-C mRNA and increased VEGF-C protein levels, together with the decrease of global translation initiation in tumors mediated by 4E-BP and eIF2a, suggested a stress-specific mechanism of regulation of VEGF-C translation, such as an IRES-dependent translation process.
Structure Probing of the 5
0 UTR mRNA of VEGF-C We therefore explored if VEGF-C might be translated via IRESdependent regulation. In order to analyze if the 5 0 UTRs of the human and murine VEGF-C contained conserved structural features, the secondary structures of both RNAs were studied by using ''selective 2 0 -hydroxyl acylation analyzed by primer extension'' (SHAPE) analysis to obtain information on the RNA (C) Putative secondary structure of the murine 5 0 UTR of VEGF-C mRNA, as predicted on the basis of the ribose reactivities toward SHAPE and the reactivities of adenines at N1 and cytosines at N3 toward DMS. For each nucleotide, the level of reactivity toward SHAPE is indicated in red, yellow, or black font character for strong, medium, or weak reactivity, respectively. The cleavage sites induced by ribonucleases V1, T1, or T2 are indicated by arrows. Motifs 2 and 3 are colorcoded as in (A).
(legend continued on next page) secondary structure at single nucleotide resolution. SHAPE takes advantage of the fact that only flexible nucleotides are reactive toward hydroxyl-selective electrophiles, whereas constrained nucleotides are unreactive. We used as chemical probing reagents benzoyl cyanide in order to provide information on the flexibility of each ribose (Mortimer and Weeks, 2009 ) and dimethyl sulfate (DMS), which methylates single-stranded cytosines at N3 and adenines at N1 ( Figure S2A ). To footprint and probe the RNA structure, we also took advantage of the enzymatic cleavage by RNase T1 (which cleaves single-stranded RNA after unpaired guanines residues), RNase T2 (cleaving single-stranded RNA after unpaired nucleotides with a preference for adenines), and RNase V1 (cleaving base-paired nucleotide residues in a non-sequence-specific manner) ( Figure S2A ). This analysis revealed that the 5 0 UTRs were highly structured because of a high GC content (Figures 3A and 3B; Figures S2A and S2B) . However, the concomitant presence of RNase V1 cleavages and of single-strand specific cuts, together with the sensitivity to modifications by DMS in the SHAPE analysis, suggested that these RNAs do not fold into a unique fixed structure but are able to adopt alternative conformations at equilibrium. Nevertheless, based on the quantification of the DMS and SHAPE reactivities, the most representative of the putative secondary structures of the murine 5 0 UTR is shown in Figure 3C . Using sequence alignment, we observed three highly conserved regions between the human and murine 5 0 UTRs ( Figure 3A ). Interestingly, SHAPE analysis revealed that two of these motifs adopted the same structure, since the reactivity pattern of the conserved residues was nearly identical ( Figure 3B ; Figure S2B ). These motifs, located at the same distance from the initiation codon in human and murine RNAs, might be appropriate for binding of trans-acting factor(s) necessary to activate IRESdependent translation.
The 5
0 UTR of VEGF-C Exhibits IRES Activity We then explored if the putative IRES sequences in the human and murine 5 0 UTR of the VEGF-C mRNAs were translationally active and cloned these sequences in a double luciferase bicistronic vector ( Figure 3D ) (Cré ancier et al., 2000) . In this vector, the first Renilla luciferase (LucR) cistron is translated by a capdependent mechanism, while the second firefly luciferase (LucF) cistron can be translated only if an IRES is present between the two cistrons. We used bicistronic vectors containing the encephalomyocarditis virus (EMCV) IRES sequence since it is not or only minimally regulated in mammalian cells, and we also used the VEGF-A IRES since it is activated by hypoxia (Bornes et al., 2007) (the VEGF-A data are discussed below). An empty control bicistronic vector, containing a sequence without IRES activity between the two cistrons, was inactive (Figure 3D ; Figure S2C ). Control RT-PCR analysis showed that both proteins were translated from a single mRNA transcript, since comparable amounts of LucR and LucF mRNA were measured ( Figures 3E and 3F ), indicating that a cryptic promoter or splicing event did not influence the results (Martineau et al., 2004) .
To quantify the IRES activity in human and murine VEGF-C 5 0 UTR sequences in vivo, Capan-1, 4T1, and LLC tumor cells were transduced with the bicistronic lentiviral vectors and injected subcutaneously (Capan-1, LLC) or orthotopically in the mammary fat pad (4T1). We used the human VEGF-C 5 0 UTR for the human cell line (Capan-1) and the murine VEGF-C 5 0 UTR for the murine cell lines (4T1, LLC). Transduction of the bicistronic vector did not affect tumor growth ( Figures S2D and  S2E ). The VEGF-C IRES activity was quantified by measuring the LucF/LucR ratio as a parameter of the relative contribution of IRES-dependent versus cap-dependent translation after 7, 14, and 21 days. The IRES activity levels at day 14 and 21 were expressed relative to the IRES activity at day 7. These experiments revealed an IRES activity for both human and murine VEGF-C 5 0 UTRs ( Figures 3G and 3H ). Furthermore, this IRES activity increased during tumor progression, especially in breast and lung tumors, while the EMCV IRES activity changed only minimally in 4T1 tumors (1.68-fold), e.g., less than the VEGF-C IRES activity in these tumors (3.75-fold).
The VEGF-C IRES Activity Is Higher in Metastatic Lymph Nodes Analysis of the LYVE-1-positive lymphatic area in Capan-1, 4T1, and LLC tumors showed that lymphangiogenesis in lymph nodes was minimal at 3 days after inoculation but progressively increased from 7 days onward ( Figures 4A-4J ). This raised the question whether VEGF-C protein synthesis was increased in metastatic lymph nodes. However, substantial numbers of metastatic cytokeratin-positive tumor cells were detected in draining lymph nodes of Capan-1 and 4T1 tumors only from 14 days onward and of LLC tumors only from 21 days onward, i.e., later than the first signs of increased lymphangiogenesis in metastatic lymph nodes ( Figures 4K-4N ). Previous reports already documented that lymph node lymphangiogenesis precedes lymph node metastasis, presumably because primary tumors release VEGF-C in the lymph fluid of efferent lymphatics (Hirakawa, 2009) .
We also explored whether tumor cells might upregulate VEGF-C production to higher levels, once they had intravasated and traveled through lymph vessels to the lymph node, and therefore analyzed the VEGF-C IRES activity in draining lymph nodes to which tumor cells metastasized. In order to compare the IRES activity in tumors and metastatic lymph nodes, the firefly/Renilla luciferase ratio in each tumor type was normalized See also Figure S2 .
to the value of 1, both for the EMCV and VEGF-C IRES, and the IRES activities in the lymph nodes were expressed as a fold induction over the IRES activity in the tumor. This analysis revealed that compared to primary tumors, the VEGF-C IRES activity in metastatic lymph nodes was 5-, 7-, and 18-fold higher in the Capan-1, 4T1, and LLC tumor models at 14, 14, and 21 days after tumor inoculation, respectively, while the EMCV IRES activity was not affected ( Figure 4O ). These findings suggested that the lymphatic milieu influenced VEGF-C translation in tumor cells.
Lymph Vessels Are Hypoxic and Develop Nearby Hypoxic Tumor Cells
We then sought to determine why the lymphatic milieu enhanced the VEGF-C IRES activity in metastatic tumor cells. Since lymphatics are known to be hypoxic (Guzy et al., 2008; Ivanovic, 2009 ) and IRES elements are activated in cellular stress conditions such as hypoxia (Braunstein et al., 2007; Komar and Hatzoglou, 2011; Pestova et al., 2001; Sachs, 2000; Silvera and Schneider, 2009; Spriggs et al., 2010; Vagner et al., 2001) , we explored whether hypoxia affected IRES-dependent initiation of translation of VEGF-C. We first explored a possible link between hypoxia and lymphatic development and therefore double stained tumors for the hypoxyprobe pimonidazole and the lymphatic markers LYVE-1 or podoplanin. Already at an early stage of tumor development (in <5 mm 3 tumors), the pancreas, breast, and lung cancer models contained hypoxic regions, which became more widespread and stained more strongly after 2 weeks (Figures 5A-5C ). Immunoblotting for HIF-1a confirmed activation of this hypoxia-inducible transcription factor (Figure 5D) . In all cancer models, lymph vessels developed in proximity of hypoxic tumor cell clusters (Figures 5E-5G) . Unlike blood endothelial cells, lymphatic endothelial cells also stained positively for pimonidazole, indicating that lymph vessels are hypoxic (Figures 5H-5J ; Figures S3A-S3F ).
Hypoxia Induces VEGF-C Expression by a Nontranscriptional Mechanism
We then studied the regulation of IRES-dependent VEGF-C translation by hypoxia. Immunostaining revealed that VEGF-C and LucF were expressed predominantly in pimonidazole-positive hypoxic tumor areas in vivo ( Figures 6A-6F) . To study the effect of hypoxia on VEGF-C expression in vitro, we exposed LLC, Capan-1, or 4T1 tumor cells to 1% oxygen or to cobalt chloride (CoCl 2 ), known to activate hypoxia signaling. Hypoxia reduced VEGF-C mRNA levels in LLC and 4T1 cells while not affecting its levels in Capan-1 cells ( Figures 6G-6I ). In LLC and 4T1 cells, hypoxia increased the protein levels of VEGF-C and of hypophosphorylated 4E-BP1, suggesting increased VEGF-C production despite a decrease in cap-dependent initiation of translation ( Figures 6J and 6K ). In Capan-1 cells, VEGF-C protein levels were comparable in hypoxic conditions, though 4E-BP1 dephosphorylation was increased, suggesting that the reduced cap-dependent initiation of VEGF-C translation was balanced off by an increase in IRES-dependent initiation of VEGF-C translation ( Figures 6J and 6K ). In each cell line, eIF2a phosphorylation was increased by hypoxia, suggesting that hypoxia downregulated global mRNA translation ( Figures 6J and 6K ). Since hypoxia increased the VEGF-C IRES activity in all human and murine tumor lines (also in the Capan-1 cells, in which VEGF-C levels did not increase) ( Figures 6L-6N) , hypoxia thus induced a switch from cap-dependent to IRES-dependent initiation of VEGF-C translation. Similar results were obtained when we used CoCl 2 ( Figure 6O ). Phosphorylation of eIF2a inhibits the EMCV IRES activity (Sanz et al., 2013) and the increased eIF2a phosphorylation levels might thus be responsible for the inhibition of the EMCV IRES activity in hypoxia, while the variable EMCV IRES activity in hypoxia in distinct tumor cell lines likely reflects celltype-dependent regulation of this IRES activity, which has been recognized previously (Pilipenko et al., 2000) .
The VEGF-C IRES Activity Is Reduced in More Oxygenated Tumors
We then explored whether tumor oxygen levels in vivo influenced the switch between cap-dependent VEGF-C translation (in oxygenated conditions) versus IRES-dependent VEGF-C translation (in hypoxic conditions). We therefore used prolyl hydroxylase domain protein-2 (PHD2) +/À mice, in which tumor hypoxia is reduced because of normalization of tumor blood vessels and improved tumor vessel perfusion (Mazzone et al., 2009) , hypothesizing that the VEGF-C IRES activity would be reduced in these mice. We thus implanted bicistronic luciferase vector-transduced LCC tumor cells in wild-type (WT) and PHD2 +/À mice. Tumor growth of cancer cells, transduced with VEGF-C-or EMCV-IRES vectors, was comparable in WT and PHD2 +/À mice ( Figure S4A ), consistent with reports that PHD2 haplodeficiency did not affect tumor growth (Mazzone et al., 2009) . Also, staining for the hypoxia marker pimonidazole demonstrated that hypoxia levels were lower in EMCV IRESand VEGF-C IRES-expressing tumors in PHD2 +/À mice than in WT mice ( Figures 7A, 7D , and 7G). Compared to tumors in WT mice, tumors in PHD2 +/À mice had similar VEGF-C immunoreactive protein levels, which colocalized in part with the pimonidazole-positive hypoxic regions, showing that both normoxic and hypoxic tumor cells produced VEGF-C ( Figures 7B, 7C , 7E, 7F, and 7H). Immunoblotting confirmed these findings ( Figure S4B ). However, a reduced fraction of (T) VEGF-C IRES activity in Capan-1 cell lines in vitro incubated under normoxia or hypoxia and treated with or without siRNA against HIF-1a or a scrambled siRNA control (mean ± SEM; n = 5; ***p < 0.001).
(U) VEGF-A IRES activity in Capan-1 tumors in vivo revealing increased IRES activity with tumor progression (mean ± SEM; n = 8-10; *p < 0.005).
(V) Quantification of staining for firefly luciferase (LucF) revealed that VEGF-A IRES activity was lower in LLC tumors in PHD2 +/À mice than in WT mice. The activity of EMCV IRES was not affected (mean ± SEM; n = 6; *p < 0.01). Note: since the data shown in Figure 7V and Figure 7O were generated in the same experiments, the EMCV control data are the same. (W and X) qRT-PCR for VEGF-A showing increased mRNA levels in hypoxic conditions in Capan-1 (C) and LLC (D) tumor cells in vitro (mean ± SEM; n = 6; *p < 0.05). Scale bar represents 50 mm (all). See also Figure S4 .
reduced in more oxygenated tumors of PHD2 +/À mice (Mazzone et al., 2009 ), the residual HIF-1a levels may still promote capdependent translation, since HIF-1a induces the transcription of the cap-binding factor eIF-4E (Yi et al., 2013) .
HIF-1a-Independent Hypoxic Induction of VEGF-C Synthesis To explore if VEGF-C protein production in hypoxic conditions was HIF dependent, we used a small interfering RNA (siRNA) against human HIF-1a (siHIF) to silence HIF-1a expression, which reduced HIF-1a protein levels to nearly undetectable levels in hypoxic Capan-1 tumor cells ( Figure 7S ). Silencing of HIF-1a also reduced the expression levels of VEGF-A, phosphoglycerate kinase (PGK), hexokinase-2, and the glucose transporter GLUT-1, all known HIF-1a target genes ( Figure S4E ). Despite the strong decrease of the HIF-1a levels in hypoxic Capan-1 tumor cells transfected with siHIF ( Figure 7S ), VEGF-C protein levels were maintained in hypoxic conditions ( Figure 7S ), whereas the VEGF-C IRES activity was not affected by HIF-1a silencing ( Figure 7T ). Thus, these data suggest that the posttranscriptional induction of VEGF-C via IRES was independent of HIF-1a.
Regulation of VEGF-A Expression by Hypoxia
For reasons of comparison, we also studied the relative importance of the cap-dependent versus IRES-dependent translation of VEGF-A in hypoxia. Previous in vitro studies documented that VEGF-A translation relies on cap-dependent mechanisms in normoxia and on IRES-dependent mechanisms in hypoxia (Bornes et al., 2004) . Transgenic mouse lines, expressing reporter genes under the control of IRESs, also revealed that VEGF-A translation in ischemic muscle partly depends on the IRES activity (Bornes et al., 2007) . However, it is unknown whether IRES-dependent translation of VEGF-A can also occur in tumors or metastatic lymph nodes. When tumor cells, stably transduced with a bicistronic lentiviral vector containing the VEGF-A IRES sequence, were injected in vivo, the VEGF-A IRES activity levels were detectable and increased during tumor progression ( Figure 7U ). The VEGF-A IRES activity was sensitive to oxygen levels in tumors in vivo, since tumors (transduced with lentiviral bicistronic vectors containing VEGF-A IRES) had lower VEGF-A IRES activity levels in PHD2 +/À mice, as revealed by staining for firefly luciferase (Figure 7V ). This was not influenced by the tumor size, since tumor growth was not affected by the PHD2 genotype or type of bicistronic vector (VEGF-A-or EMCV-IRES) ( Figure S4F ). However, different from VEGF-C, regulation of VEGF-A expression also relied on transcriptional upregulation in hypoxic conditions. Indeed, VEGF-A mRNA levels were increased in tumor cells in hypoxia (Figures 7W and 7X) and also increased during tumor progression in vivo, both at the protein and mRNA levels ( Figures S4G-S4J) . Thus, unlike VEGF-A, the expression of which is upregulated in hypoxia at the transcriptional and translational level, the expression of VEGF-C in hypoxia is regulated by translational, but not by transcriptional, mechanisms.
DISCUSSION
We identified a translational regulation of VEGF-C production in hypoxic conditions, both in primary tumors and in (pre)-metastatic lymph nodes, that is distinct from previously identified mechanisms of how hypoxia stimulates lymphangiogenesis.
Tumor Cells Metastasizing via Hypoxic Lymphatics
Induce VEGF-C For tumor cells to spread to distant organs via lymphatics, they induce lymphangiogenesis. However, since tumors are often deprived of oxygen and lymphatics are extremely hypoxic (Guzy et al., 2008; Ivanovic, 2009) , tumor cells must have mechanisms to stimulate lymph vessel growth in hypoxic conditions. Our findings demonstrate that tumor cells can upregulate VEGF-C protein levels in hypoxic conditions in vitro and in vivo and that lymph vessels grew in and around hypoxic tumor areas, where VEGF-C was produced. While hypoxia often upregulates protein levels via HIF-1a-dependent gene transcription, this study shows that hypoxia augments VEGF-C protein levels via a HIF-1a-independent effect on VEGF-C IRES-dependent initiation of translation.
Hypoxia Regulates VEGF-C Protein Levels via an IRES-Dependent Activity
We demonstrate that murine and human VEGF-C mRNAs are translated by IRES-dependent initiation of translation in hypoxic tumor areas during tumor development in vivo. Sequence alignment revealed that murine and human VEGF-C 5 0 UTRs share three highly conserved motifs. Interestingly, probing the RNA secondary structures by SHAPE analysis showed that two of these motifs adopt the same two-dimensional structure, since the reactivity pattern of the conserved residues was nearly identical. These motifs, located at the same distance from the initiation codon, might be appropriate for binding of specific trans-acting factor(s), necessary to activate IRES-dependent translation. Use of a bicistronic vector provided functional evidence that the 5 0 UTR of murine and human VEGF-C mRNA indeed functioned as IRES sequences to initiate cap-independent translation of the VEGF-C mRNA. Thus, translation of the VEGF-C mRNA in normoxia occurs via cap-and/or IRES-dependent mechanisms. In hypoxia, when global translation is suppressed through dephosphorylation of 4E-BP1 and increased phosphorylation of eIF2a, IRES-mediated mRNA translation is activated, leading to an overall increase in VEGF-C protein levels.
VEGF-C IRES Activity Is Higher in Lymph Nodes
Previous studies reported that expression of VEGF-C by cancer cells promotes tumor and lymph node lymphangiogenesis as well as metastasis (Hirakawa et al., 2005 (Hirakawa et al., , 2007 . Even before metastatic tumor cells reach the sentinel lymph nodes, VEGF-C, released by malignant cells of the primary tumor into the lymphatic circulation, stimulates lymphangiogenesis in lymph nodes at a distance (Hirakawa et al., 2005 (Hirakawa et al., , 2007 . Using luciferase reporters of posttranscriptional VEGF-C regulation, we observed that the VEGF-C IRES firefly luciferase activity was increased in lymph nodes at the time when they were colonized by metastatic tumor cells. Notably, however, the induction of the VEGF-C IRES activity was higher in tumor cells that had metastasized to the lymph nodes than in tumor cells that were present in the primary tumors. Lymphangiogenesis was also more extensive in metastatic lymph nodes than in primary tumors. These data indicate that the lymph node milieu stimulates VEGF-C expression. Since lymphatics are highly hypoxic, the hypoxic milieu seems to be of key importance to activate IRES-dependent VEGF-C translation.
HIF-1a-Independent Regulation of VEGF-C Translation in Hypoxia Hypoxia signaling is well known to stimulate angiogenesis, in part by promoting HIF-1a dependent transcription of VEGF-A as well as by stimulating IRES-dependent VEGF-A translation (Bornes et al., 2007; Huez et al., 2001) . In contrast, VEGF-C transcript levels were reduced, yet VEGF-C protein levels were increased, in hypoxia by switching from cap-dependent to IRES-dependent VEGF-C translation. Notably, this regulation seemed to be independent of HIF-1a, since near-complete silencing of HIF-1a to levels sufficient to lower HIF-1a target gene transcription did not abrogate the hypoxia-induced posttranscriptional IRES-activated translation of VEGF-C mRNA and production of VEGF-C protein. Different molecular mechanisms thus evolved to ensure production of VEGF-A and VEGF-C, two closely related and homologous members of the VEGF family.
Hypoxic Lymph Vessels Ensure Lymphangiogenesis in Cancer Our findings may also be relevant to understand how tumor cells have developed mechanisms to ensure spreading via lymphatics in oxygen-deprived conditions. Lymph vessels are severely hypoxic, not only because they lack oxygen-carrying red blood cells, but also because they reside in very hypoxic regions in tissues and tumors (Guzy et al., 2008; Ivanovic, 2009) . Such a hypoxic milieu suppresses cap-dependent mRNA translation of VEGF-C in tumor cells, traveling inside lymphatics to the lymph nodes. However, by switching to IRES-dependent initiation of translation of VEGF-C, tumor cells can upregulate the production of this key lymphangiogenic factor in hypoxia and thereby ensure increased growth of lymph vessels via which they metastasize. Hence, tumor cells have adopted mechanisms to stimulate lymphangiogenesis when metastasizing through hypoxic lymph vessels and lymph nodes.
EXPERIMENTAL PROCEDURES
All human tissue was used under approval from the Human Subjects Institutional Review Board of the University of Toulouse III. More detailed procedures are described in Supplemental Experimental Procedures.
Tissue Specimens
In total, 15 primary human breast cancer specimens and their associated lymph nodes were collected from pretreatment surgical resections (Rangueil Hospital, Toulouse, France). Sample collection was approved by the INSERM Institutional Review Board (DC-2008-463) and Research State Department (Ministè re de la Recherche, ARS, CPP2, authorization AC-2008-820).
Cell Culture
Cell culture of Capan-1 pancreatic carcinoma cells, 4T1 breast carcinoma, and LLC cells under normoxia or hypoxia (1% O 2 or 300 mM CoCl 2 ) was as described in the Supplemental Experimental Procedures.
Tumor Studies and Immunohistochemical Phenotyping
Animal experiments were conducted in accordance with recommendations of the European Convention for the Protection of Vertebrate Animals used for experimentation and according to the INSERM IACUC (France) and the KU Leuven (Belgium) guidelines for laboratory animal husbandry. All animal experiments were approved by the local branch Inserm Rangueil-Purpan of the Midi-Pyré né es ethics committee, France (protocol 091037615), or by the Institutional Animal Care and Research Advisory Committee of the KU Leuven, Leuven, Belgium (protocol P166/2011). The LLC syngenic tumor model in C57Bl6 mice, Capan-1 xenograft model in NMRI nude mice, syngenic orthotopic 4T1 breast carcinoma model in Balb/c mice, and the collection and immunohistological analysis of tumor and lymph nodes was performed as detailed in the Supplemental Experimental Procedures.
RNA and Protein Analysis SHAPE Analysis
In-vitro-transcribed RNA was prepared and subjected to SHAPE analysis as previously described (Helfer et al., 2013) (Mortimer and Weeks, 2009 ) and further detailed in the Supplemental Experimental Procedures.
RNA Analysis
Expression of human and murine VEGF-C, VEGF-A, hexokinase II, Glut1, PGK, LucR, and LucF was by SYBR green quantitative RT-PCR (Table S1) as described in the Supplemental Experimental Procedures. Protein Analysis VEGF-C protein levels in Capan-1 tumor extracts were measured by ELISA (R&D Systems).
Lentivector Construction and Luciferase Reporter Gene Assay
Cloning of the cDNAs coding human and murine VEGF-C 5 0 UTR, VEGF-A 5 0 UTR, and EMCV 5 0 UTR into the bicistronic lentivectors expressing Renilla luciferase under the cytomegalovirus promoter and firefly luciferase under the control of the respective 5 0 UTR IRES, and cell transduction was as described in the Supplemental Experimental Procedures. In vitro or ex vivo luciferase assays on cell or tissue lysates were performed using the DualLuciferase Assay System kit (Promega).
siRNA and Cell Transfection siRNA-mediated silencing of human HIF1a was done using a pool of siRNAs as listed in the Supplemental Experimental Procedures. Transfection of Capan-1 cells and verification of silencing by immunoblotting was as described in the Supplemental Experimental Procedures.
Statistical Analysis
All statistical analyses were performed with a two-tailed Student's t test or one-way ANOVA. All experiments were performed three times, with one exception, where the incidence of metastasis is reported as the average ± SEM of three separate animal experiments. All other data presented are of one representative experiment. 
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